Ebpay生命医药出版社

      Ebpay生命

      100763

      论文已发表

      提 交 论 文


      注册即可获取Ebpay生命的最新动态

      注 册



      IF 收录期刊



      • 3.3 Breast Cancer (Dove Med Press)
      • 3.4 Clin Epidemiol
      • 2.5 Cancer Manag Res
      • 2.9 Infect Drug Resist
      • 3.5 Clin Interv Aging
      • 4.7 Drug Des Dev Ther
      • 2.7 Int J Chronic Obstr
      • 6.6 Int J Nanomed
      • 2.5 Int J Women's Health
      • 2.5 Neuropsych Dis Treat
      • 2.7 OncoTargets Ther
      • 2.0 Patient Prefer Adher
      • 2.3 Ther Clin Risk Manag
      • 2.5 J Pain Res
      • 2.8 Diabet Metab Synd Ob
      • 2.8 Psychol Res Behav Ma
      • 3.0 Nat Sci Sleep
      • 1.8 Pharmgenomics Pers Med
      • 2.7 Risk Manag Healthc Policy
      • 4.2 J Inflamm Res
      • 2.1 Int J Gen Med
      • 4.2 J Hepatocell Carcinoma
      • 3.7 J Asthma Allergy
      • 1.9 Clin Cosmet Investig Dermatol
      • 2.7 J Multidiscip Healthc



      更多详情 >>





      已发表论文

      FBLN4  作为与原发性胶质母细胞瘤长期和短期存活率相关的候选基因

       

      Authors Li F, Li YP, Zhang K, Li Y, He P, Liu YJ, Yuan H, Lu H, Liu J, Che S, Li Z, Bie L

      Received 13 July 2016

      Accepted for publication 27 September 2016

      Published 16 January 2017 Volume 2017:10 Pages 387—395

      DOI http://doi.org/10.2147/OTT.S117165

      Checked for plagiarism Yes

      Review by Single-blind

      Peer reviewers approved by Dr Akshita Wason

      Peer reviewer comments 3

      Editor who approved publication: Dr XuYu Yang

      Background: Glioblastoma multiforme (GBM) is the most common malignant and lethal type of primary central nervous system tumor in humans. In spite of its high lethality, a small percentage of patients have a relatively good prognosis, with median survival times of 36 months or longer. The identification of clinical subsets of GBM associated with distinct molecular genetic profiles has made it possible to design therapies tailored to treat individual patients.
      Methods: We compared microarray data sets from long-term survivors (LTSs) and short-term survivors (STSs) to screen for prognostic biomarkers in GBM patients using the WebArrayDB platform. We focused on FBLN4 , IGFBP-2 , and CHI3L1 , all members of a group of 10 of the most promising, differentially regulated gene candidates. Using formalin-fixed paraffin-embedded GBM samples, we corroborated the relationship between these genes and patient outcomes using methylation-specific polymerase chain reaction (PCR) for MGMT  methylation status and quantitative reverse transcription PCR for expression of these genes.
      Results: Expression levels of the mRNAs of these 3 genes were higher in the GBM samples than in normal brain samples and these 3 genes were significantly upregulated in STSs compared to the levels in LTS samples (<0.01). Furthermore, Kaplan–Meier analysis showed that the expression patterns of FBLN4  and IGFBP-2  serve as independent prognostic indicators for overall survival (<0.01 and <0.05, respectively).
      Conclusion: To our knowledge, this is the first report describing FBLN4  as a prognostic factor for GBM patient survival, demonstrating that increased GBM survival time correlates with decreased FBLN4  expression. Understanding FBLN4  expression patterns could aid in the creation of powerful tools to predict clinical prognoses of GBM patients.
      Keywords: glioblastoma, FBLN4 , IGFBP-2 , tumor marker, prognosis





      Download Article[PDF]